SynthesisAntimicrobial resistance and infection control2024
Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis.
Synthesis in Antimicrobial resistance and infection control, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Prevalence of colistin resistance in clinicalFuture microbiology · 2025Pooled it
- Prevalence, trends, and molecular insights into colistin resistance among gram-negative bacteria in Egypt: a systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2025Pooled it
- Colistin-based combination therapy versus monotherapy for carbapenem-resistant gram-negative bacterial infections: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Combined effect of eravacycline and omadacycline with other antimicrobial agents against Acinetobacter Baumannii.The Journal of antibiotics · 2026Article
- Evolution of Antimicrobial Resistance in Neonatal Sepsis: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Antibacterial and anti-biofilm mechanisms of 1,8-cineole against colistin-resistant Acinetobacter baumannii: an integrated in vitro, gene expression, and in silico study.Scientific reports · 2026Article
- Synergistic and antagonistic interactions between colistin and cell-free supernatants of Lactobacillus species against clinical isolates of Acinetobacter baumannii.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Colistin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Antibiotic resistance among Gram-negative bacteria in bloodstream infections in Shiraz, Iran (2012-2023).AMB Express · 2026Article
- Molecular Characterizations of Carbapenem Resistance and Colistin Heteroresistance in Multidrug-Resistant Acinetobacter baumannii.Current microbiology · 2026Article
- Global distribution of mcr-carrying bacteria: an analysis of genomic data.BMC medical genomics · 2026Article
- Bacteriological Profile and Antibiotic Sensitivity Pattern of Burn Wounds in a Tertiary Burn Care Center.Cureus · 2026Article
- Antibiofilm activity of a chionodracine-derived peptide by NMR-based metabolomics of cell-free supernatant of Acinetobacter baumannii clinical strains.FEBS open bio · 2026Article
- Colistin-resistance amongJAC-antimicrobial resistance · 2026Review
- Combinations of colistin and bacteriocins prevent the selection of colistin resistance in Acinetobacter baumannii.Communications biology · 2026Article
- Colistin Resistance: From Laboratory Research to Modern Clinical Management.Antibiotics (Basel, Switzerland) · 2026Review
- Molecular basis of carbapenem and colistin resistance andMicrobiology spectrum · 2026Article
- Case Report: Successful salvage therapy with sulbactam-durlobactam combined with meropenem for carbapenem-resistant Acinetobacter baumannii bloodstream infection in a child after failure of allogeneic hematopoietic stem cell transplantation.Frontiers in pediatrics · 2026Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe development of colistin resistance in Acinetobacter baumannii during treatment has been identified in certain patients, often leading to prolonged or recurrent infections. As colistin, is the last line of therapy for A. baumannii infections that are resistant to almost all other antibiotics, colistin-resistant A. baumannii strains currently represent a significant public health threat, particularly in healthcare settings where there is significant selective pressure.
aimThe aim of this study was to comprehensively determine the prevalence of colistin resistance in A. baumannii from clinical samples. Regional differences in these rates were also investigated using subgroup analyses.
methodThe comprehensive search was conducted using "Acinetobacter baumannii", "Colistin resistant" and all relevant keywords. A systematic literature search was performed after searching in PubMed, Embase, Web of Science, and Scopus databases up to April 25, 2023. Statistical analysis was performed using Stata software version 17 and sources of heterogeneity were evaluated using I
resultAccording to the results, the prevalence of resistance to colistin among A. baumannii isolates was 4% (95% CI 3-5%), which has increased significantly from 2% before 2011 to 5% after 2012. South America had the highest resistance rate to this antibiotic. The broth microdilution method had the highest level of resistance, while the agar dilution showed the lowest level.
conclusionsThis meta-analysis found a low prevalence of colistin resistance among A. baumannii isolates responsible for infections worldwide from 2000 to 2023. However, there is a high prevalence of colistin-resistant isolates in certain countries. This implies an urgent public health threat, as colistin is one of the last antibiotics available for the treatment of infections caused by XDR strains of A. baumannii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.